Ireland
--:--IST
Latest
Ireland Second in Chemical-Pharma Index, but Weaknesses Show PulseAI of Belfast Says FDA Cleared Its Wearable ECG AI Airmid Éireann 1.6 Adds India and China Trials, Swiss Prices Irish Cancer Trial Enrolment at 2.9%, Under Half 6% Target FDA Accelerated Approval for J&J's Head and Neck Cancer Drug Korea Misses 2026 Biosimilar Approvals, Bets on Keytruda Ireland Second in Chemical-Pharma Index, but Weaknesses Show PulseAI of Belfast Says FDA Cleared Its Wearable ECG AI Airmid Éireann 1.6 Adds India and China Trials, Swiss Prices Irish Cancer Trial Enrolment at 2.9%, Under Half 6% Target FDA Accelerated Approval for J&J's Head and Neck Cancer Drug Korea Misses 2026 Biosimilar Approvals, Bets on Keytruda
Clinical Trials in the USA / NCT05234177
Recruiting Observational

Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

NCT05234177 · tracked via the Priya Life Science USA tracker
Sponsor
Tempus AI
Phase
Observational
Started
2022-06-21
Last updated
2025-05-06

Condition(s) studied

Colorectal Cancer

Investigational drug(s) / intervention(s)

Observation

Observation: No intervention

Study summary

The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Known or suspected colorectal adenocarcinoma (Stage I to IVA disease) * Planning to undergo or has undergone a surgical resection for suspected adenocarcinoma of the colon or rectum with curative intent. * 18 years old or older * Willing and able to provide informed consent * Willing to have additional blood samples collected during routine surveillance visits Exclusion Criteria: * Not willing to have additional blood samples collected * Pathology that is not consistent with colorectal adenocarcinoma

Primary outcome measure(s)

  • Recurrence-Free Survival — 2 years
    Recurrence-Free Survival as assessed by standard radiographic imaging, measured from the day of completion of definitive treatment to first radiographic recurrence or death

Trial sites (20)

FacilityCityRegionStatus
Mercy Clinic Oncology - Fort Smith Fort Smith Arkansas Recruiting
MemorialCare Fountain Valley California Recruiting
The Center for Cancer and Blood Disorders Bethesda Maryland Recruiting
Mercy Clinic Oncology and Hematology - Joplin Joplin Missouri Recruiting
Mercy Clinic Cancer and Hematology - Chub O'Reilly Cancer Center Springfield Missouri Recruiting
Washington University School of Medicine St Louis Missouri Recruiting
Mercy Clinic Oncology and Hematology - Sindelar Cancer Center St Louis Missouri Recruiting
Mercy Clinic Oncology and Hematology - David C. Pratt Cancer Center St Louis Missouri Recruiting
Nebraska Cancer Specialists Omaha Nebraska Recruiting
Southeastern Medical Oncology Center Goldsboro North Carolina Recruiting
Aultman Hospital Canton Ohio Recruiting
TriHealth Cancer Institute Cincinnati Ohio Recruiting
Ohio State University Columbus Ohio Recruiting
OhioHealth Research Institute Columbus Ohio Recruiting
Toledo Clinic Cancer Center Toledo Ohio Recruiting
Mercy Clinic Oncology and Hematology - Coletta Oklahoma City Oklahoma Recruiting
Cancer Care Associates of York York Pennsylvania Recruiting
Utah Cancer Specialists Salt Lake City Utah Recruiting
University of Washington / Fred Hutchinson Cancer Center Seattle Washington Recruiting
ThedaCare Regional Cancer Center Appleton Wisconsin Recruiting

More Tempus AI trials in the USA

TEMPUS ARIES: A Biobank Registry Platform Study in Oncology Recruiting
Tempus Priority Study: A Pan-tumor Observational Study Active, not recruiting
GEMINI-NSCLC: NSCLC Biomarker Study Recruiting
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension Recruiting
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC) Recruiting

Other trials for the same condition

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors Recruiting
Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer Active, not recruiting
A Randomised Controlled Trial to Evaluate the Impact of Complement Theory's Live CoActive Exercise Coaching and Personalized Digital Application on Cancer Survivors' Quality of Life Active, not recruiting
IDOV-Immune for Advanced Solid Tumors Recruiting
FOG-001 in Locally Advanced or Metastatic Solid Tumors Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05234177 on ClinicalTrials.gov ↗ ← All trials in the USA